ARMATA PHARMACEUTICALS, INC. Letters of Credit Outstanding, Amount
ARMATA PHARMACEUTICALS, INC. (ARMP) had Letters of Credit Outstanding, Amount of $4.00 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Other Liabilities
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-08-12
- 2026-06-30: Letters of Credit Outstanding, Amount $4.00M.
- 2026-03-31: Letters of Credit Outstanding, Amount $4.00M.
- 2022-03-31: Letters of Credit Outstanding, Amount $5.00M.
- 2021-10-28: Letters of Credit Outstanding, Amount $5.00M.
| Period end | Letters of Credit Outstanding, Amount |
|---|---|
| 2026-06-30 | $4.00M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $4.00M 10-Q · filed 2026-05-13 |
| 2022-03-31 | $5.00M 10-Q · filed 2022-11-09 |
| 2021-10-28 | $5.00M 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |